Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Q1 2025 earnings

Reported May 1, 2025 · Before market open

Revenue$137.3MMiss by $21.7M
EPS-$3.32Beat by $0.30
Revenue estimate$158.9M
EPS estimate-$3.62

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$404.2M
EPS estimate-$0.86

Financials

Q1 2025

Income statement

See full
Revenue$137.3M—
Operating income-$79.3M+47.8%
Net income-$73.2M+50.4%
EPS (diluted)-$3.32+55.0%

Balance sheet

See full
Cash & equivalents$188.6M-69.7%
Total debt$131.4M+0.7%
Total equity$710.6M-16.5%
Total assets$996.6M-7.9%

Cash flow

See full
Operating cash flow-$88.9M+40.4%
CapEx--100%
Free cash flow-$88.9M+40.5%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$7.31B+32.8%
Enterprise value$7.26B+44.7%
P/S23×—

Profitability

See full
Operating margin-134%—
Net margin-123.4%—
FCF margin-124.9%—

Returns & leverage

See full
Return on equity-50.2%-15.2pp
Debt / equity0.2×0.0×
Current ratio5.9×-3.5×

Segments

By segment

See full
Reportable Segment$137.3M—

FAQ

When did Madrigal Pharmaceuticals, Inc. report Q1 2025 earnings?
Madrigal Pharmaceuticals, Inc. (MDGL) reported Q1 2025 earnings on May 1, 2025 before market open.
What were Madrigal Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
Madrigal Pharmaceuticals, Inc. reported revenue of $137.3M and eps of $-3.32 for Q1 2025.
Did Madrigal Pharmaceuticals, Inc. beat estimates in Q1 2025?
Revenue missed the consensus estimate of $158.9M by $21.7M. EPS beat the consensus estimate of $-3.62 by $0.30.
How did Madrigal Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 55.0% from $-7.38.
Where can I find Madrigal Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-021314) and the 10-Q periodic report (0001628280-25-021356) directly on SEC EDGAR. The filing index links above go to sec.gov.